Quantitative Gait Analysis Using a Motorized Treadmill System Sensitively Detects Motor Abnormalities in Mice Expressing ATPase Defective Spastin by Connell, James W et al.
RESEARCH ARTICLE
Quantitative Gait Analysis Using a Motorized
Treadmill System Sensitively Detects Motor
Abnormalities in Mice Expressing ATPase
Defective Spastin
JamesW. Connell, Rachel Allison, Evan Reid*
Department of Medical Genetics and Cambridge Institute for Medical Research, University of Cambridge,
Cambridge, United Kingdom
* ealr4@cam.ac.uk
Abstract
The hereditary spastic paraplegias (HSPs) are genetic conditions in which there is progres-
sive axonal degeneration in the corticospinal tract. Autosomal dominant mutations, includ-
ing nonsense, frameshift and missense changes, in the gene encoding the microtubule
severing ATPase spastin are the most common cause of HSP in North America and north-
ern Europe. In this study we report quantitative gait analysis using a motorized treadmill sys-
tem, carried out on mice knocked-in for a disease-associated mutation affecting a critical
residue in the Walker A motif of the spastin ATPase domain. At 4 months and at one year of
age homozygous mutant mice had a number of abnormal gait parameters, including in
stride length and stride duration, compared to heterozygous and wild-type littermates. Gait
parameters in heterozygous animals did not differ from wild-type littermates. We conclude
that quantitative gait analysis using the DigiGait system sensitively detects motor abnormal-
ities in a hereditary spastic paraplegia model, and would be a useful method for analyzing
the effects of pharmacological treatments for HSP.
Introduction
Hereditary spastic paraplegias (HSP) are genetically determined subtypes of motor neuron dis-
ease that are characterized by dying-back degeneration of the axons of the corticospinal tract
[1–5]. In humans, they cause a progressive spastic gait abnormality that can begin from child-
hood to late adult life. No treatments for the HSPs are available presently, but potential thera-
peutic approaches, such as inhibition of BMP signaling or manipulation of microtubule
dynamics, have been suggested [4, 6]. Thus there is a need to develop appropriate model sys-
tems and reliable methodologies with which to test therapeutic effects.
Mutations in SPAST/SPG4, which encodes the microtubule severing ATPase spastin, are
the most frequent cause of HSP [7]. In North America and northern Europe, mutations in
this gene account for up to 40% of autosomal dominant uncomplicated HSP and around 10%
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of sporadic cases [8–11]. SPAST mutations are also found in other geographical regions and
ethnic populations [12–15]. The mutational spectrum associated with spastin-HSP is broad;
frameshift, nonsense and splice site mutations, as well as larger genomic re-arrangements
causing whole-exon deletions, are frequent [8, 9, 11]. Missense mutations are also common
and these cluster in the ATPase domain [4]. Although other mechanisms have been suggested
[16], this broad mutational spectrum suggests a haplo-insufficiency disease mechanism. The
description of pathological genomic deletions involving the entire coding region of the gene,
making protein expression from the affected allele impossible, strongly supports this idea
[11].
To sever microtubules, current models suggest that the spastin ATPase domains hexamerise
into a ring structure with a central pore [17–19]. ATP hydrolysis is then coupled to microtu-
bule severing, by a mechanism involving the interaction between central pore residues and the
C-terminal tail of tubulin [17, 18]. The known ATPase domain missense mutations appear to
fall into several molecular pathogenic groups; they may block ATP binding or hydrolysis, pre-
vent hexamerisation by interfering with ATPase domain protomer-protomer interactions or
affect the interaction between pore residues and tubulin [17, 18].
Two spastin mouse models have been published. Tarrade et al. used a gene targeting
approach to generate mice deleted for exons 5–7 of spastin [20]. The deletion caused a new
splicing event linking exons 4 and 8, resulting in a frameshift that introduced a stop codon
shortly after the exon 4–8 junction. In homozygous mice this caused complete absence of the
spastin protein, probably because the truncated transcript is subject to nonsense-mediated
decay. In cultured primary neurons from homozygous mutant mice, and to a lesser degree, het-
erozygous mice, this caused an axonal swelling phenotype that predominantly involved the dis-
tal axon. Homozygous mutant mice developed a mild, late onset motor defect. At 22 months of
age footprint analysis of spontaneously walking homozygous mutant mice demonstrated a
slightly increased step length and decreased uniformity of step length and step alternation
compared to controls. In addition, between 15 and 24 months old, aerobic motor capacity
declined faster in the homozygous mutants than in control mice. Kasher et al. also described a
spastin loss-of-function model, in this case involving a mutation in the exon 7 splice donor site
that caused exon 7 to be skipped from the transcript [21]. Again, homozygous mutant mice
had no detectable spastin protein. These mice showed very similar axonal swellings to those
described previously. The mice developed a mild gait abnormality detected during spontaneous
running. This consisted of a slight but progressive increase in the distance between the hin-
dlimbs that was first detectable at 7 months of age.
In this study we examine gait phenotypes in a mouse model knocked-in for a spastin
ATPase missense mutation, encoding the murine equivalent (N384K) of the human disease-
associated N386K missense mutation [8]. Murine and human spastin ATPase domains are
identical, and the N386K mutation affects a residue in the entirely conserved (from humans to
plants) canonical Walker A motif, which forms the phosphate binding loop (P-loop) of the
ATPase domain [18]. Structural studies on Drosophila and human spastin have confirmed that
the N386 residue forms a critical part of the P-loop of the nucleotide binding region [18, 22].
Mutations in P-loop residues affect nucleotide binding or hydrolysis, and consistent with this,
the N386K mutation almost completely blocks ATP hydrolysis but appears to allow ATP bind-
ing [23]. As in previous spastin-HSP models, axonal swellings developed in primary neurons
cultured from homozygous mutant mice. We used a motorized treadmill based digital analysis
system (DigiGait) to characterize and quantify gait metrics, which revealed several subtle but
significant abnormalities of gait parameters in homozygous mutant mice. Our results highlight
the utility of this approach in sensitively detecting gait abnormality in models of HSP.
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Materials and Methods
Knock-in mouse generation and breeding
A schematic diagram of the targeting strategy is shown in Fig 1A. We had generated (at
Taconic Artemis) mice knocked-in for a mutation in exon 8 (Spast c.1152c<a (p.Asn384Lys),
NM_001162870.1, CCDS50181.1) encoding an N384K amino acid substitution, on a C57BL/6
genetic background. Briefly, exons 5–8 of the spast locus were replaced by a positive selection
cassette containing the mutation. This cassette contained two positive selection markers (neo-
mycin and puromycin resistance) flanked by flippase (Flp) recognition target F3 or FRT sites,
in introns 4 and 7 respectively. It also incorporated loxP sites in introns 4 and 7, providing the
possibility of future deletion of these exons by crossing with Cre-recombinase expressing mice,
to generate a spastin loss-of-function model. The targeting vector was generated using BAC
clones from the C57BL/6J RPCI-23 BAC library and transfected into TaconicArtemis C57BL/
6N Tac ES cell line. ES clones were analyzed by Southern Blotting to confirm correct recombi-
nation and single integration, according to standard procedures. Homologous recombinant
clones were used to generate chimeric animals by injection into C57BL/6 blastocysts. Highly
chimeric mice were bred to C57BL/6 Flp-Deleter mice, to remove the selective markers. Germ-
line transmission was identified by the presence of black, strain C57BL/6 offspring (G1) and
was confirmed by PCR of ear biopsies using the following primer pairs:
2201_31: AAACTGTTCCCAAGGCATCC and 2201_32: GTGTCAGTGTGCATAAGTCATGG,
which detect the presence or absence of the loxP site in intron 4,
2084_29: GTCATAGCTGTAACCAACTTCTG and 2084_30: ACCAAACACATGCGAGTGAGG,
which amplify an exon 8 sequence containing the mutation. The presence of the mutation was
confirmed by sequencing (Source BioScience) (Fig 1B).
Mice were maintained in accordance with United Kingdom and European Union regula-
tions. Animal work for this study was approved by the University of Cambridge Ethical Review
Committee and was carried out under project licenses (80/2304 and 70/7888) granted by the
United Kingdom Home Office under the Animals (Scientific Procedures) Act 1986. The Uni-
versity of Cambridge is a designated establishment for breeding and for scientific procedures
under the Animals (Scientific Procedures) Act 1986.
Mice were housed under temperature-controlled and specific-pathogen-free conditions, with
a 12-hour light/dark cycle and free access to drinking water and food. They were maintained on a
C57BL/6 background.We interbred heterozygous mice to generate wild-type (termed spastwt/wt),
heterozygous (termed spastinN384K/wt) and homozygous (termed spastinN384K/N384K) mice. The
cohort of mice analysed in the behavioural studies was made up of groups of spastwt/wt,
spastN384K/wt and spastinN384K/N384K littermates. Embryonic or day old mice used to generate pri-
mary neurons were sacrificed by decapitation, adult mice were sacrificed by cervical dislocation.
Antibodies
The following antibodies were used: Mouse monoclonal anti-MAP2 (abcam ab11268), mouse
monoclonal anti-acetlylated tubulin (Sigma-Aldrich T7541)), rabbit polyclonal anti-spastin
(spastin86-340, raised in house to amino acids 86–340 of spastin [24, 25]), rabbit monoclonal
anti-GAPDH (Cell Signalling 2118, clone 14C10), mouse monoclonal anti-Tau-5 antibody
(Abcam ab80579).
Generating tissue lysates and western blotting
Cortex from mouse brain was homogenized in ice cold lysis buffer (25mMHEPES pH 7.4, 1mM
EDTA, 150mMNaCl, 0.5% TX100, protease inhibitors) using a pellet pestle (Sigma-Aldrich).
Gait Analysis in Spastin Mouse Model
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Fig 1. SpastinN384K/N384K knock-in mouse generation and validation. A) Schematic diagram of strategy
used to generate spastinN384K allele. Numbering refers to spastin exons. Puro = puromycin resistance
cassette, Neo = neomycin resistance cassette, Flp = flippase, FRT = flippase recognition target, UTR =
untranslated region. B) DNA sequencing of PCR product generated using primers designed to amplify
fragment of spastin exon 8 from genomic DNA of a wild-type mouse and spastinN384K/N384K littermate. C)
Immunoblotting versus spastin of lysate or pellet fraction from foetal brain tissue (E17), frommice of the
Gait Analysis in Spastin Mouse Model
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Homogenate was centrifuged at 5000rpm for 15 min and supernatant centrifuged at 49000rpm
for 1 hour. Protein concentration was quantified using BCA protein assay (Pierce) and total
spastin levels were analysed in 30μg of lysate protein using SDS-PAGE. Pellet fractions were
resuspended in 300μl sample buffer and 15μl was analyzed using SDS-PAGE, with equal lane
loading confirmed by Coomassie staining. Gels were blotted onto PVDFmembrane and blocked
in 5% non-fat dried milk in TBS-Tween. Membrane was incubated with primary antibodies and
HRP-conjugated secondary antibodies in blocking buffer and HRP-signal detected with Super-
Signal1West Pico Chemiluminescent Substrate using X-Ray film (Fuji Medical). Immunoblot
bands were quantified using ImageJ software.
Primary Neuron Culture
Cortical neurons were obtained from E17 mouse embryos or day old pups and cultured on
Poly-D-Lysine coated glass coverslips in Neurobasal medium (Gibco/Invitrogen) with B27
supplement (Gibco/Invitrogen) and L-glutamine (Sigma-Aldrich). After seven days in culture
neurons were fixed in 3.7% formaldehyde and processed for immunofluorescence microscopy.
Immunofluorescence microscopy
To quantify axonal swellings, formaldehyde fixed neurons on coverslips were permeabilised
with 0.1% TX100 in PBS and blocked in 5% fetal calf serum in PBS for 1 hour. Coverslips were
incubated with primary antibodies and Alexa Fluor1 conjugated secondary antibodies in
blocking buffer and mounted onto glass slides using Prolong1 Gold antifade reagent with
DAPI (Molecular Probes). Neurons were visualized using a Zeiss Axioimager Z2 Wide-field
upright microscope and axonal swellings were quantified per 250 nuclei. Axonal swellings were
identified as acetylated tubulin positive, MAP2 negative regions on a single axon which were
greater than twice the diameter of the axon.
Tissue genotyping
Genomic DNA was purified from mouse ear biopsies using DNeasy1Blood and Tissue kit
(Qiagen). PCR was performed using primer pairs 2201_31 and 2201_32 on an Applied Biosys-
tems GeneAmp19700 PCR system. PCR products were analysed on a 1.5% agarose gel and
genotype was identified by the presence or absence of bands at 235bp (wt/wt), 235 and 427bp
(wt/N384K), 427bp (N384K/N384K).
Modified Shirpa Analysis
The following behaviours chosen from the modified Shirpa analysis were recorded for each
mouse at 1 year old: body position, tremor, palpebral closure, coat appearance, presence of
whiskers, presence of defecation, transfer arousal, locomotor activity in arena by measuring
number of squares entered with all 4 feet in 3 seconds, tail elevation, touch escape, positional
passivity, trunk curl, limb grasping and evidence of biting [26].
DigiGait analysis
DigiGait equipment was purchased fromMouse Specifics, Inc (Boston) and analysis was car-
ried out as previously described [27]. Briefly, each mouse was placed on a motor-driven
genotypes indicated. The histogram shows corresponding densitometry of the spastin bands in the lysate
(n = 3 per genotype, p-values generated by paired t-tests). GAPDH immunoblotting or Coomassie staining
serve to verify equal loading of lanes. Size bars indicate molecular weight in kD.
doi:10.1371/journal.pone.0152413.g001
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treadmill with a transparent treadmill belt and imaged from beneath with a high-speed digital
video camera. A minimum of three seconds of movie is required for digigait analysis, and mice
that could not run at the chosen speed for that duration were deemed to have failed to complete
the test. Colour images were converted to their binary matrix equivalents and the areas of the
moving paws relative to the belt and camera were calculated throughout each stride. This was
used to generate a dynamic gait signal of the paw placement relative to the treadmill belt and
camera. Each limb’s gait signal was used to calculate the stride duration (time duration of one
complete stride for the paw under analysis). This was broken down into subcomponents of
stance duration (the time duration when the paw is in contact with treadmill) and swing dura-
tion (the time duration when the paw is above the walking surface and not in contact with the
belt). Stance duration further comprises the braking phase (time duration from initial paw con-
tact with the treadmill to maximum paw contact) and propulsion duration (time duration
from maximum paw contact to lifting from treadmill). Stride width was defined as the perpen-
dicular distance between the centroids of each set of axial paws during peak stance. Gait sym-
metry was measured as the ratio of forelimb stepping frequency to hind limb stepping
frequency.
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism 5.01 for Windows (GraphPad Soft-
ware, San Diego) statistical software. Specific statistical tests used are described in the relevant
figure or table captions. Briefly, for behavioral analysis, one-way (to analyse effects of a single
variable, i.e. genotype) or two-way (to analyse effects of two variables, i.e. gender and genotype)
ANOVA was performed to compare effects across 3 groups (spastwt/wt, spastN384K/wt or
spastN384K/N384K). In certain cases ANOVA was supplemented with Bonferroni post-test for
comparison of individual pairs of genotypes. Fischer’s exact test was used to analyse the contin-
gency table of digigait success or failure by genotype. Differences in spastin immunoblot band
densitometry were assessed by paired t-tests. For p-values,  =<0.05,  =<0.01,  =<0.001,
 =< 0.0001. Error bars in all graphs represent mean ± standard error of the mean (S.E.M.).
Results
Generation of spastin knock-in mice
We used a gene targeting approach to generate a mouse model on a C57BL/6 background,
which was knocked in for a mutation (1152c<a) in exon 8 of murine spastin. This mutation
encodes an N384K missense change in the spastin protein, corresponding to the human dis-
ease-causing missense mutation N386K [8]. The presence of the mutation was confirmed by
sequencing (Fig 1B). Spastin protein was expressed in brain tissue from spastinwt/wt, spas-
tinN384K/wt and spastinN384K/N384K animals (Fig 1C).
Axonal swellings in primary neurons from knock-in mice
In light of the primary neuron axonal swelling phenotype observed in previous spastin mouse
models, we examined whether similar swellings were present in primary neurons derived from
spastinN384K/N384K mice. We saw prominent neurite swellings in spastinN384K/N384K primary
neurons and the affected neurites never labeled for the somatodendritic marker MAP2 but
labeled with the axonal marker tau, confirming them as axons (Fig 2A–2C). SpastinN384K/wt
neurons did not develop significantly more axonal swellings than wild-type littermates (Fig
2B). These results demonstrate the presence of a cell-autonomous neuronal pathology, and are
consistent with findings in other spastin mouse models. Furthermore, they demonstrate no
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Fig 2. SpastinN384K/N384K mice develop axonal swellings. A) Day 7 in vitro primary cortical neurons from animals with the genotypes indicated labeled with
antibody to acetylated tubulin. DAPI staining (blue) was used to label nuclei. Examples of swellings seen in spastinN384K/N384K neurons are shown in the
boxed areas, which are magnified in the right hand panels. B) Primary cortical neurons were labeled as in A) and the number of swellings per 250 nuclei was
quantified in animals with the genotypes shown (n = 3 repeats per genotype). Mean number of swellings per 250 nuclei ± S.E.M.: spastwt/wt = 16.0 ± 1.53,
spastN384K/wt = 16.3 ± 3.28 and for spastN384K/wt 62 ± 4.04. P-values were generated by 1-way ANOVA with Bonferroni post-test for comparison of individual
pairs of genotypes. C) Day 7 in vitro primary cortical neurons from spastinN384K/N384K mice were labeled with the antibodies indicated. Swellings
(arrowheads) were always MAP2 negative or tau positive, indicating that they were present in axons. Scale bars = 20μm.
doi:10.1371/journal.pone.0152413.g002
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obvious dominant negative or gain-of-function effects of the mutant protein in heterozygous
neurons.
Gait abnormality in spastinN384K/N384K mice
Heterozygous mutant mice bred normally, and both heterozygous and homozygous mutants
showed no obvious defects in size or morphology. However, at 1 year old, spastinN384K/N384K
mice were significantly lighter than heterozygous or wild-type mice (Fig 3A). We characterized
the locomotor phenotype of a cohort of 1 year old male and female littermate spastinN384K/wt
and spastinN384K/N384K animals, as well as littermate spastwt/wt mice. No obvious phenotypic
differences between the different genotypes were detected on modified primary SHIRPA exam-
ination. We also examined the maximum running speed of the animals at 1 year using an accel-
erating treadmill, with treadmill speeds increasing by 1cm/s at 10s intervals, beginning from
5cm/s. Again, we found no significant effect of genotype.
We next used the DigiGait analysis system to quantify gait parameters while the mice were
running on a treadmill. This system images the ventral side of mice as they move on a motor-
ized transparent treadmill belt and quantifies spatial and temporal gait indices [27]. These
include the duration for a complete stride (stride duration), as well as individual components
of the stride, such as the duration of swing and stance phases (see Methods section for a full
description of the gait parameters analysed). As many rodent gait parameters are influenced by
running speed [28], we used a constant speed of 18cm/s. This running speed was chosen to
optimize the number of animals able to complete the testing, as at higher speeds increasing
numbers of mice of all genotypes were not able to keep up with the treadmill, most likely
because of their relatively advanced age. Even so, some animals were unable to run at 18cm/s
and so were excluded from analysis, but the proportion excluded did not significantly differ by
genotype (Table 1). Using 2-way ANOVA, we found significant effects of genotype, but not of
gender in a number of basic hind limb gait metrics (Table 2 and Fig 3). In particular, the spas-
tinN384K/N384K mice had a significantly lengthened mean stride duration, and the increase was
almost entirely due to an elongation of the swing phase of gait (Table 2, Fig 3B–3D and S1–S4
Movies). These changes altered the profile of a typical step in the spastinN384K/N384K mice, com-
pared to the other two genotypes (Fig 3E). Mean stride length was also significantly increased
in the spastinN384K/N384K mice, consistent with the need to maintain a constant speed with a
slower stride (Table 2 and Fig 3F).
To analyse whether there was evidence that the N384K mutation acted in a dominant fash-
ion, we next analysed the key gait metrics that were influenced by genotype, specifically to
determine whether heterozygous mutant animals differed significantly from homozygous
mutant or wild-type animals. As the 2-way ANOVA analysis demonstrated no effect of gender
on these parameters, we pooled data from males and females, and compared the effect of each
genotype against the other two. While we saw significant differences between wild-type and
spastinN384K/N384K animals, and between spastinN384K/wt and spastinN384K/N384K, we saw no sig-
nificant difference between spastinwt/wt and spastinN384K/wt mice (Table 3). We thus saw no
dominant effect of the mutation on the gait phenotype.
Abnormal gait parameters can be detected at 4 months old
Having characterised gait parameters in the 1-year old cohort of spastin-HSP mice, we tested
whether gait abnormalities could be detected at a younger age by analyzing gait metrics in a
separate cohort of mice at 4 months old. Of note, in wild-type mice at this age, key gait parame-
ters including stride duration, stance duration and swing duration were very similar to those
previously obtained by Digigait in a group of 3 month old C57BL/6 mice running at a similar
Gait Analysis in Spastin Mouse Model
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Fig 3. Weight and key left hindlimb gait parameters in spastinN384K/N384K mice versus littermate controls at 1 year old. Plots show values for each
animal tested with the genotypes indicated. Squares = male animals, circles = females. A) weight in grammes, B) stride duration, C) swing phase duration, D)
stance phase duration. E) Histogram showing the mean percentage of time that tested animals with the genotypes indicated spent in each phase of gait. F)
Stride length in animals with the genotypes shown. Error bars = mean ± S.E.M. Numerical p-values for corresponding statistical tests using two-way ANOVA
for the effect of gender and genotype on gait parameters are shown in Table 2. To facilitate interpretation, p-values for genotype are indicated on the plots by
* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
doi:10.1371/journal.pone.0152413.g003
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Table 1. Numbers of animals in cohort unable to complete DigiGait analysis at 1 year. p-value for asso-
ciation between genotype and completion/failure of test was not significant (Fischer’s exact test).
Genotype Completed DigiGait assessment at 18cm/s Failed DigiGait assessment at
18cm/s
spastwt/wt 10 3
spastinN384K/wt 16 6
spastinN384K/N384K 10 3
doi:10.1371/journal.pone.0152413.t001
Table 2. Weight and Quantified gait parameters in spastwt/wt, spastinN384K/wt, spastinN384K/N384Kmice at 1 year old. Values are shown for the left hind
limb unless otherwise stated; very similar results were obtained for the right hind limb. p-values for the effect of gender and genotype were calculated using two-
way ANOVA. To correct for multiple testing, the alpha value for significance was calculated by dividing 0.05 by 8, using a highly conservative assumption of 8
independent tests (many of the tests are in reality related), to give α = 0.00625. spastwt/wt n = 10 (4 male, 6 female), spastinN384K/wt n = 16 (7male, 9 female),
spastinN384K/N384K n = 10 (6 male, 4 female).
Parameter Mean ± S.E.M. for: spastwt/wt spastinN384K/wt
spastinN384K/N384K
p-value for effect of
Gender
p-value for effect of
genotype
Weight (g) 44.0 ± 1.06 0.08 0.0008
42.8 ± 1.30
36.4 ± 2.23
Mean stride duration (s) 0.31 ± 0.011 0.96 0.005
0.32 ± 0.007
0.36 ± 0.007
Mean swing phase duration (s) 0.09 ± 0.004 0.83 < 0.0001
0.10 ± 0.003
0.14 ± 0.01
Mean stance phase duration (s) 0.22 ± 0.01 0.88 0.79
0.22 ± 0.02
0.21 ± 0.01
Mean braking duration in stance phase
(s)
0.04 ± 0.0005 0.33 0.98
0.04 ± 0.002
0.04 ± 0.003
Mean propulsion duration in stance
phase (s)
0.18 ± 0.0005 0.61 0.82
0.18 ± 0.005
0.17 ± 0.004
Mean stride length (cm) 5.7 ± 0.15 0.92 0.006
5.8 ± 0.08
6.4 ± 0.04
Mean hindlimb stance width (cm) 2.8 ± 0.11 0.09 0.06
2.7 ± 0.03
3.0 ± 0.19
Mean gait symmetry ratio (1 = entirely
symmetrical)
1.01 ± 0.01 0.42 0.64
1.00 ± 0.006
1.00 ± 0.005
doi:10.1371/journal.pone.0152413.t002
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speed [29]. However, we found a significant increase in stride duration in spastinN384K/N384K
mice versus littermate controls (Table 4 and Fig 4A). This was not restricted to the swing phase
of gait, as stance phase duration was significantly increased (Table 4 and Fig 4B and 4C). Thus
overall, the gait profile was not affected by genotype (Fig 4D). Finally, as with the older mice,
Table 3. Comparison of genotypes for selected gait parameters. P-values generated using one-way ANOVA with Bonferroni post-test for multiple com-
parison of individual pairs of genotypes.
Gait Parameter p-value for spastwt/wt versus
spastinN384K/N384K
p-value for spastinN384K/wt versus
spastinN384K/N384K
p-value for spastwt/wt
versus spastinN384K/wt
Mean stride duration (s) <0.01 <0.05 n.s.
Mean swing phase
duration (s)
<0.001 <0.001 n.s.
Mean stride length (cm) <0.01 <0.05 n.s.
doi:10.1371/journal.pone.0152413.t003
Table 4. Quantified gait parameters in spastwt/wt, spastinN384K/wt, spastinN384K/N384K mice at 4 months
old. Values are shown for the left hind limb unless otherwise stated. p-values for the effect of genotype were
calculated using one-way ANOVA. To correct for multiple testing, the alpha value for significance was calcu-
lated by dividing 0.05 by 8, using a highly conservative assumption of 8 independent tests (many of the tests
are in reality related), to give α = 0.00625. N = 3 mice in each group.
Gait Parameter Mean ± S.E.M. for: spastwt/wt
spastinN384K/wt spastinN384K/N384K
p-value for effect of
genotype
Mean stride duration (s) 0.30 ± 0.005 0.002
0.32 ± 0.006
0.38 ± 0.01
Mean swing phase duration (s) 0.11 ± 0.006 0.088
0.11 ± 0.003
0.12 ± 0.004
Mean stance phase duration (s) 0.20 ± 0.01 0.0014
0.21 ± 0.02
0.25 ± 0.01
Mean braking duration in stance
phase (s)
0.033 ± 0.003 0.16
0.036 ± 0.006
0.046 ± 0.009
Mean propulsion duration in
stance phase (s)
0.16 ± 0.002 0.0003
0.17 ± 0.002
0.21 ± 0.006
Mean stride length (cm) 5.5 ± 0.09 0.0012
5.7 ± 0.1
6.8 ± 0.2
Mean hindlimb stance width (cm) 2.6 ± 0.07 0.52
3.0 ± 0.29
2.9 ± 0.18
Mean gait symmetry ratio
(1 = entirely symmetrical)
1.02 ± 0.02 0.28
1.04 ± 0.01
1.08 ± 0.04
doi:10.1371/journal.pone.0152413.t004
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Fig 4. Key left hindlimb gait parameters in spastinN384K/N384K mice versus littermate controls at 4 months old. Plots show values for each animal
tested with the genotypes indicated. A) stride duration, B) swing phase duration, C) stance phase duration. D) Histogram showing the mean percentage of
time that tested animals with the genotypes indicated spent in each phase of gait. E) Stride length in animals with the genotypes shown. Numerical values for
corresponding statistical tests using one-way ANOVA for the effect of genotype on gait parameters are shown in Table 4. To facilitate interpretation, p-values
for genotype are indicated on the plots by * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Error bars = mean ± S.E.M
doi:10.1371/journal.pone.0152413.g004
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there was a significant increase in stride length in spastinN384K/N384K compared to wild-type
and heterozygous littermates, consistent with the need to run at the same speed with a slower
stride duration (Table 4 and Fig 4E). We also analysed, as described above for the 1 year old
mice, whether there was any dominant effect of the mutation in heterozygous mice, but found
no significant difference between wild-type and heterozygous mice for any gait parameter
analysed.
Discussion
We generated a novel genetically modified mouse knocked-in for a disease-associated missense
mutation that results in expression of an ATPase-defective form of spastin, thus modelling a
class of spastin mutations that has not previously been analysed in mammalian in vivo systems.
In contrast to our model, in which enzymatically dead spastin is expressed, previous mouse
models have involved loss of the spastin protein, caused either by a deletion of exons 5–7, or
defective splicing of exon 7 [20, 21]. Nevertheless, like these earlier models, in our model
homozygous mutant animals had axonal swellings in cortical neuronal cultures (which contain
the target cells of HSP) and a gait abnormality. The gait abnormality was evident on quantita-
tive gait testing, but was subtle as it was not detected on modified Shirpa testing. Many gait
metrics change with running speed, and so to allow direct comparison of metrics between ani-
mals, gait was assessed at a constant speed [28]. At both 4 months and one year old we found
that the spastinN384K/N384K mice had a symmetrical gait, but that they had a significantly longer
stride duration than control mice. Step length was also increased in the spastinN384K/N384K
mice, and this is consistent with findings in one of the knock-out models [20].
The identification of quantifiable gait abnormalities as early as 4 months old in the spas-
tinN384K/N384K mice will be useful in assessing the therapeutic response to future pharmacologi-
cal agents designed to treat HSP. Indeed, some gait metrics differed by genotype significantly
in 4 month old mice but not in 1 year old mice (e.g. stance duration). With the caveat that we
examined relatively few 4 month old animals, so that we may by chance have under-estimated
the inter-animal variability in gait metrics at this age, we speculate that this may be because
degenerative changes affecting gait parameters may be more prevalent in the older animals, so
increasing the variability of results (compare for example the variability in wild-type mouse
results for stride duration in Fig 3B versus Fig 4A). This would tend to obscure subtle differ-
ences between control and homozygous knock-in mice.
In contrast to the situation in humans, where heterozygous spastin mutations are sufficient
to cause HSP, we saw no frank axonal swellings or convincing locomotor phenotype in mice
heterozygous for the spastin N384K-expressing allele, although in the 4 month old animals
there was a trend towards several gait metrics for heterozygous animals being intermediate
between wild-type and homozygous mutant values. While mice may require increased dosage
of mutant alleles to drive development of neurodegenerative diseases within their short (com-
pared to humans) lifespan [30], significant effects on axonal swelling or gait phenotypes might
have been expected in heterozygous mice if the mutation acted via a dominant negative or
gain-of-function pathological mechanism. Thus while not formally excluding them from play-
ing a role in human patients, our results provide no strong support for these mechanisms of
disease acting in our mouse model.
Conclusions
We have developed a novel mouse model expressing an ATPase-defective form of spastin.
Homozygous mutant mice develop a subtle but reliably detectable gait abnormality. Our results
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highlight the utility of quantitative gait analysis using treadmill systems in identifying gait
abnormalities in models of hereditary spastic paraplegia.
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